MedTrace Logo

Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f®

NCT01794208 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 267

Last updated 2021-05-07

No results posted yet for this study

Summary

The aim of the current study was the determination of the recommended standard treatment dose of FSH-GEX(TM) in women undergoing intracytoplasmic sperm injection (ICSI) treatment as assessed by follicle growth.

Conditions

Interventions

DRUG

Follitropin Epsilon

DRUG

Follitropin Alfa

Sponsors & Collaborators

  • Glycotope GmbH

    lead INDUSTRY

Principal Investigators

  • Study Director · Glycotope GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
37 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-08
Primary Completion
2013-07-31
Completion
2013-07-30

Countries

  • Germany
  • Hungary

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01794208 on ClinicalTrials.gov